Lipocine Other Non Cash Items vs Change To Netincome Analysis

LPCN Stock

USD 3.63 0.09 2.54%

Lipocine financial indicator trend analysis is infinitely more than just investigating Lipocine recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lipocine is a good investment. Please check the relationship between Lipocine Other Non Cash Items and its Change To Netincome accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipocine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.

Other Non Cash Items vs Change To Netincome

Other Non Cash Items vs Change To Netincome Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lipocine Other Non Cash Items account and Change To Netincome. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Lipocine's Other Non Cash Items and Change To Netincome is -0.37. Overlapping area represents the amount of variation of Other Non Cash Items that can explain the historical movement of Change To Netincome in the same time period over historical financial statements of Lipocine, assuming nothing else is changed. The correlation between historical values of Lipocine's Other Non Cash Items and Change To Netincome is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Non Cash Items of Lipocine are associated (or correlated) with its Change To Netincome. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Change To Netincome has no effect on the direction of Other Non Cash Items i.e., Lipocine's Other Non Cash Items and Change To Netincome go up and down completely randomly.

Correlation Coefficient

-0.37

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Other Non Cash Items

Change To Netincome

Most indicators from Lipocine's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lipocine current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipocine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.As of the 16th of February 2025, Selling General Administrative is likely to grow to about 5.8 M, while Tax Provision is likely to drop 411.40.

	2022	2023	2024	2025 (projected)
Total Operating Expenses	11.8M	15.1M	17.3M	9.3M
Cost Of Revenue	8.6M	10.2M	11.7M	9.4M

Total Operating Expenses Cost Of Revenue

Lipocine fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Debt	Retained Earnings	Accounts Payable	Cash	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Net Tangible Assets	Retained Earnings Total Equity	Short Term Investments	Capital Surpluse	Treasury Stock	Property Plant And Equipment Net	Non Current Assets Total
Total Assets		0.4	0.44	0.96	-0.27	-0.49	-0.53	0.48	0.49	0.39	0.99	0.42	0.47	0.12	0.64	0.2	1.0	0.42	-0.07	0.9	-0.56	0.65	0.64	-0.53	0.2	0.54
Other Current Liab	0.4		0.63	0.35	-0.07	0.0	-0.36	0.18	-0.04	0.08	0.38	0.15	0.2	-0.02	0.38	0.21	0.41	0.15	0.11	0.33	-0.38	0.47	0.38	-0.53	0.25	0.12
Total Current Liabilities	0.44	0.63		0.22	-0.22	0.1	-0.69	0.63	0.03	0.14	0.33	0.41	0.37	0.57	0.64	0.84	0.44	0.41	-0.42	0.21	-0.74	0.34	0.64	-0.7	-0.18	0.22
Total Stockholder Equity	0.96	0.35	0.22		-0.26	-0.56	-0.39	0.35	0.5	0.4	0.99	0.36	0.43	-0.06	0.53	-0.07	0.96	0.36	0.09	0.94	-0.4	0.65	0.53	-0.38	0.31	0.53
Other Liab	-0.27	-0.07	-0.22	-0.26		-0.15	0.62	-0.6	0.19	-0.72	-0.24	-0.79	-0.78	-0.2	-0.6	-0.06	-0.24	-0.79	-0.26	-0.4	0.59	-0.4	-0.59	0.35	-0.43	-0.32
Net Debt	-0.49	0.0	0.1	-0.56	-0.15		-0.18	-0.1	-0.97	0.25	-0.58	0.2	0.19	0.08	0.05	0.21	-0.54	0.2	0.14	-0.48	-0.18	0.26	0.05	-0.13	0.03	0.19
Retained Earnings	-0.53	-0.36	-0.69	-0.39	0.62	-0.18		-0.8	0.12	-0.66	-0.45	-0.86	-0.84	-0.42	-0.96	-0.56	-0.52	-0.86	-0.15	-0.51	0.99	-0.6	-0.96	0.84	-0.4	-0.34
Accounts Payable	0.48	0.18	0.63	0.35	-0.6	-0.1	-0.8		0.15	0.62	0.43	0.83	0.78	0.42	0.77	0.52	0.49	0.83	-0.04	0.5	-0.79	0.29	0.77	-0.5	0.19	0.15
Cash	0.49	-0.04	0.03	0.5	0.19	-0.97	0.12	0.15		-0.34	0.54	-0.23	-0.24	0.12	-0.01	0.01	0.55	-0.23	-0.34	0.4	0.1	-0.31	-0.01	0.06	-0.2	-0.2
Other Assets	0.39	0.08	0.14	0.4	-0.72	0.25	-0.66	0.62	-0.34		0.36	0.91	0.93	-0.03	0.66	-0.04	0.34	0.91	0.46	0.57	-0.61	0.67	0.65	-0.35	0.57	0.56
Cash And Short Term Investments	0.99	0.38	0.33	0.99	-0.24	-0.58	-0.45	0.43	0.54	0.36		0.37	0.42	0.02	0.58	0.07	0.99	0.36	0.01	0.93	-0.47	0.62	0.58	-0.46	0.27	0.47
Common Stock Total Equity	0.42	0.15	0.41	0.36	-0.79	0.2	-0.86	0.83	-0.23	0.91	0.37		0.99	0.24	0.82	0.24	0.39	1.0	0.33	0.53	-0.82	0.57	0.81	-0.55	0.5	0.43
Common Stock Shares Outstanding	0.47	0.2	0.37	0.43	-0.78	0.19	-0.84	0.78	-0.24	0.93	0.42	0.99		0.19	0.82	0.17	0.44	0.99	0.41	0.59	-0.8	0.64	0.81	-0.57	0.58	0.44
Other Current Assets	0.12	-0.02	0.57	-0.06	-0.2	0.08	-0.42	0.42	0.12	-0.03	0.02	0.24	0.19		0.35	0.66	0.12	0.24	-0.45	-0.08	-0.46	-0.09	0.35	-0.34	-0.32	0.0
Other Stockholder Equity	0.64	0.38	0.64	0.53	-0.6	0.05	-0.96	0.77	-0.01	0.66	0.58	0.82	0.82	0.35		0.46	0.64	0.82	0.15	0.67	-0.95	0.66	1.0	-0.81	0.41	0.4
Total Liab	0.2	0.21	0.84	-0.07	-0.06	0.21	-0.56	0.52	0.01	-0.04	0.07	0.24	0.17	0.66	0.46		0.2	0.24	-0.6	-0.11	-0.62	0.06	0.46	-0.57	-0.39	0.06
Total Current Assets	1.0	0.41	0.44	0.96	-0.24	-0.54	-0.52	0.49	0.55	0.34	0.99	0.39	0.44	0.12	0.64	0.2		0.39	-0.07	0.9	-0.54	0.61	0.64	-0.53	0.21	0.46
Common Stock	0.42	0.15	0.41	0.36	-0.79	0.2	-0.86	0.83	-0.23	0.91	0.36	1.0	0.99	0.24	0.82	0.24	0.39		0.33	0.53	-0.82	0.57	0.81	-0.55	0.5	0.43
Property Plant Equipment	-0.07	0.11	-0.42	0.09	-0.26	0.14	-0.15	-0.04	-0.34	0.46	0.01	0.33	0.41	-0.45	0.15	-0.6	-0.07	0.33		0.25	-0.07	0.28	0.14	-0.11	0.93	-0.12
Net Tangible Assets	0.9	0.33	0.21	0.94	-0.4	-0.48	-0.51	0.5	0.4	0.57	0.93	0.53	0.59	-0.08	0.67	-0.11	0.9	0.53	0.25		-0.49	0.67	0.66	-0.42	0.47	0.45
Retained Earnings Total Equity	-0.56	-0.38	-0.74	-0.4	0.59	-0.18	0.99	-0.79	0.1	-0.61	-0.47	-0.82	-0.8	-0.46	-0.95	-0.62	-0.54	-0.82	-0.07	-0.49		-0.6	-0.95	0.86	-0.33	-0.36
Short Term Investments	0.65	0.47	0.34	0.65	-0.4	0.26	-0.6	0.29	-0.31	0.67	0.62	0.57	0.64	-0.09	0.66	0.06	0.61	0.57	0.28	0.67	-0.6		0.66	-0.57	0.43	0.75
Capital Surpluse	0.64	0.38	0.64	0.53	-0.59	0.05	-0.96	0.77	-0.01	0.65	0.58	0.81	0.81	0.35	1.0	0.46	0.64	0.81	0.14	0.66	-0.95	0.66		-0.81	0.4	0.4
Treasury Stock	-0.53	-0.53	-0.7	-0.38	0.35	-0.13	0.84	-0.5	0.06	-0.35	-0.46	-0.55	-0.57	-0.34	-0.81	-0.57	-0.53	-0.55	-0.11	-0.42	0.86	-0.57	-0.81		-0.37	-0.23
Property Plant And Equipment Net	0.2	0.25	-0.18	0.31	-0.43	0.03	-0.4	0.19	-0.2	0.57	0.27	0.5	0.58	-0.32	0.41	-0.39	0.21	0.5	0.93	0.47	-0.33	0.43	0.4	-0.37		-0.05
Non Current Assets Total	0.54	0.12	0.22	0.53	-0.32	0.19	-0.34	0.15	-0.2	0.56	0.47	0.43	0.44	0.0	0.4	0.06	0.46	0.43	-0.12	0.45	-0.36	0.75	0.4	-0.23	-0.05

Click cells to compare fundamentals

Lipocine Account Relationship Matchups

Lipocine fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	25.4M	52.5M	37.5M	23.0M	26.5M	29.7M
Other Current Liab	1.7M	2.0M	1.1M	1.2M	1.4M	1.5M
Total Current Liabilities	6.6M	5.6M	1.7M	2.6M	3.0M	3.4M
Total Stockholder Equity	15.3M	45.6M	35.6M	20.4M	23.4M	24.6M
Net Debt	(13.6M)	(639.7K)	(3.1M)	(4.8M)	(5.5M)	(5.7M)
Retained Earnings	(172.0M)	(172.7M)	(183.4M)	(199.8M)	(179.8M)	(170.8M)
Accounts Payable	1.6M	1.3M	600.4K	1.4M	1.6M	1.7M
Cash	19.2M	3.0M	3.1M	4.8M	4.3M	4.1M
Cash And Short Term Investments	19.7M	44.6M	32.5M	22.0M	25.3M	26.6M
Common Stock Total Equity	2.2K	3.8K	7.0K	8.8K	10.2K	10.7K
Common Stock Shares Outstanding	3.3M	5.2M	5.3M	5.3M	6.1M	6.4M
Liabilities And Stockholders Equity	25.4M	52.5M	37.5M	23.0M	26.5M	29.7M
Other Current Assets	5.7M	1.5M	945.3K	773.4K	889.4K	1.5M
Other Stockholder Equity	187.4M	218.2M	219.1M	220.1M	253.2M	147.6M
Total Liab	10.0M	6.9M	1.9M	2.6M	3.0M	5.1M
Total Current Assets	25.3M	46.4M	34.1M	22.9M	26.3M	28.8M
Common Stock	7.0K	8.8K	8.9K	8.9K	10.2K	10.7K
Property Plant Equipment	19.0K	3.6K	7.2K	131.6K	118.4K	124.4K
Net Tangible Assets	6.3M	15.3M	45.6M	35.6M	41.0M	27.0M
Retained Earnings Total Equity	(138.1M)	(151.1M)	(172.0M)	(172.7M)	(155.4M)	(163.2M)
Short Term Investments	450.0K	41.7M	29.4M	17.3M	19.9M	15.1M
Capital Surpluse	147.5M	157.4M	187.4M	218.3M	251.0M	143.4M
Property Plant And Equipment Net	0.0	7.2K	131.6K	116.1K	133.5K	140.2K
Non Current Assets Total	23.8K	6.1M	3.4M	139.8K	160.8K	152.8K
Property Plant And Equipment Gross	1.1M	1.2M	1.3M	1.3M	1.5M	1.6M
Net Receivables	391.0	247.3K	659.9K	52.3K	47.0K	44.7K
Net Invested Capital	20.9M	47.9M	35.6M	20.4M	23.4M	27.8M
Net Working Capital	18.7M	40.8M	32.5M	20.2M	23.3M	25.5M
Short Long Term Debt Total	7.1M	5.6M	2.3M	17.2K	15.4K	14.7K
Capital Stock	7.0K	8.8K	8.9K	8.9K	10.2K	7.2K

When determining whether Lipocine offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lipocine's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lipocine Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lipocine Stock:

How To Invest In Lipocine

Details

Is Lipocine Stock a good investment?

Details

What is Lipocine's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipocine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.

You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipocine. If investors know Lipocine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipocine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.75)

Revenue Per Share

1.486

Quarterly Revenue Growth

137.519

Return On Assets

(0.15)

Return On Equity

(0.20)

The market value of Lipocine is measured differently than its book value, which is the value of Lipocine that is recorded on the company's balance sheet. Investors also form their own opinion of Lipocine's value that differs from its market value or its book value, called intrinsic value, which is Lipocine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipocine's market value can be influenced by many factors that don't directly affect Lipocine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Lipocine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lipocine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipocine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Lipocine Other Non Cash Items vs Change To Netincome Analysis

Other Non Cash Items vs Change To Netincome

Other Non Cash Items vs Change To Netincome Correlation Analysis

Correlation Coefficient

Other Non Cash Items

Change To Netincome

Lipocine fundamental ratios Correlations

Lipocine Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Lipocine fundamental ratios Accounts

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Common Stock	+ 1.0	Common Stock Total Equity
Capital Surpluse	+ 1.0	Other Stockholder Equity
Cash And Short Term Investments	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Total Stockholder Equity
Retained Earnings Total Equity	+ 0.99	Retained Earnings

Cash	- 0.97	Net Debt
Capital Surpluse	- 0.96	Retained Earnings
Other Stockholder Equity	- 0.96	Retained Earnings
Capital Surpluse	- 0.95	Retained Earnings Total Equity
Retained Earnings Total Equity	- 0.95	Other Stockholder Equity
Common Stock	- 0.86	Retained Earnings